(Q46148436)

19 December 2017

title

Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial (English)

1 reference

19 December 2017

Rena Vassilopoulou-Sellin

0 references

5

Bo von Schoultz

0 references

7

object named as

Rena Vassilopoulou-Sellin

0 references

Jean-Michel Foidart

3

object named as

Jean-Michel Foidart

1 reference

19 December 2017

13

Matthias W Beckmann

1 reference

19 December 2017

Peter Kenemans

1

1 reference

19 December 2017

Nigel J Bundred

2

1 reference

19 December 2017

Ernst Kubista

4

1 reference

19 December 2017

Bo von Schoultz

5

1 reference

19 December 2017

Piero Sismondi

6

1 reference

19 December 2017

Rena Vassilopoulou-Sellin

7

1 reference

19 December 2017

Cheng Har Yip

8

1 reference

19 December 2017

Jan Egberts

9

1 reference

19 December 2017

Mirjam Mol-Arts

10

1 reference

19 December 2017

Roel Mulder

11

1 reference

19 December 2017

Steve van Os

12

1 reference

19 December 2017

LIBERATE Study Group

14

1 reference

19 December 2017

publication date

23 January 2009

1 reference

19 December 2017

Lancet Oncology Commission

published in

1 reference

19 December 2017

volume

10

1 reference

19 December 2017

issue

2

1 reference

19 December 2017

page(s)

135-146

1 reference

19 December 2017

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970341-3

7 January 2021

Risk of menopause during the first year after breast cancer diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970341-3

7 January 2021

Management of menopausal symptoms in patients with breast cancer: an evidence-based approach

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970341-3

7 January 2021

Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970341-3

7 January 2021

Tibolone for postmenopausal women: systematic review of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970341-3

7 January 2021

Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970341-3

7 January 2021

Tibolone: a steroid with a tissue-specific mode of action

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970341-3

7 January 2021

Receptor profiling and endocrine interactions of tibolone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970341-3

7 January 2021

Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970341-3

7 January 2021

Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970341-3

7 January 2021

A comparative study of breast cell proliferation during hormone replacement therapy: effects of tibolon and continuous combined estrogen-progestogen treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970341-3

7 January 2021

Breast cancer and hormone-replacement therapy: the Million Women Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970341-3

7 January 2021

Hormone replacement therapy use and variations in the risk of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970341-3

7 January 2021

The effects of tibolone in older postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970341-3

7 January 2021

The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970341-3

7 January 2021

Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970341-3

7 January 2021

Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970341-3

7 January 2021

Safety of tibolone in the treatment of vasomotor symptoms in breast cancer patients--design and baseline data 'LIBERATE' trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970341-3

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970341-3

7 January 2021

Effects of tibolone and hormone replacement therapy on the breast of cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970341-3

7 January 2021

Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970341-3

7 January 2021

Selective tissue distribution of tibolone metabolites in mature ovariectomized female cynomolgus monkeys after multiple doses of tibolone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970341-3

7 January 2021

Steroid sulfatase and estrogen sulfotransferase in normal human tissue and breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970341-3

7 January 2021

Menopausal hormone therapy after breast cancer: the Stockholm randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970341-3

7 January 2021

HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970341-3

7 January 2021

Increased risk of recurrence after hormone replacement therapy in breast cancer survivors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970341-3

7 January 2021

Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970341-3

7 January 2021

Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970341-3

7 January 2021

10.1016/S1470-2045(08)70341-3

Identifiers

DOI

1 reference

19 December 2017

1 reference

19 December 2017